AU2007315943A1 - IKK-beta serine-threonine protein kinase inhibitors - Google Patents

IKK-beta serine-threonine protein kinase inhibitors Download PDF

Info

Publication number
AU2007315943A1
AU2007315943A1 AU2007315943A AU2007315943A AU2007315943A1 AU 2007315943 A1 AU2007315943 A1 AU 2007315943A1 AU 2007315943 A AU2007315943 A AU 2007315943A AU 2007315943 A AU2007315943 A AU 2007315943A AU 2007315943 A1 AU2007315943 A1 AU 2007315943A1
Authority
AU
Australia
Prior art keywords
cyclopentyl
carbamoylamino
carbamoyl
alkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007315943A
Other languages
English (en)
Inventor
Michael Hugh Charlton
Stephen John Davies
Simon Christopher Hirst
David Festus Charles Moffat
Stuart Thomas Onions
Jonathon Gareth Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chroma Therapeutics Ltd
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0621720A external-priority patent/GB0621720D0/en
Priority claimed from GB0715470A external-priority patent/GB0715470D0/en
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of AU2007315943A1 publication Critical patent/AU2007315943A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AU2007315943A 2006-11-01 2007-10-29 IKK-beta serine-threonine protein kinase inhibitors Abandoned AU2007315943A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0621720.2 2006-11-01
GB0621720A GB0621720D0 (en) 2006-11-01 2006-11-01 Inhibitors of ikk- serine-threonine protein kinase
GB0715470.1 2007-08-09
GB0715470A GB0715470D0 (en) 2007-08-09 2007-08-09 IKK- serine-threonine protein kinase inhibitors
PCT/GB2007/004114 WO2008053182A1 (en) 2006-11-01 2007-10-29 IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
AU2007315943A1 true AU2007315943A1 (en) 2008-05-08

Family

ID=39015937

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007315943A Abandoned AU2007315943A1 (en) 2006-11-01 2007-10-29 IKK-beta serine-threonine protein kinase inhibitors

Country Status (15)

Country Link
US (1) US8003695B2 (enExample)
EP (1) EP2078007B1 (enExample)
JP (1) JP2010508336A (enExample)
KR (1) KR20090077975A (enExample)
AT (1) ATE522516T1 (enExample)
AU (1) AU2007315943A1 (enExample)
BR (1) BRPI0718056A2 (enExample)
CA (1) CA2668338A1 (enExample)
DK (1) DK2078007T3 (enExample)
EA (1) EA200900616A1 (enExample)
ES (1) ES2372707T3 (enExample)
IL (1) IL198267A0 (enExample)
MX (1) MX2009004442A (enExample)
NZ (1) NZ576705A (enExample)
WO (1) WO2008053182A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) * 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
US20110039920A1 (en) * 2008-04-23 2011-02-17 Chroma Therapeutics Ltd. Inhibitors of ikk-beta serine-theronine protein kinase
US20110046210A1 (en) * 2008-04-26 2011-02-24 Chroma Therapeutics Ltd. Substituted thiopenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors
US8470889B2 (en) * 2008-11-26 2013-06-25 Trt Pharma Inc. Hybrid-ionone and curcumin molecules as anticancer agents
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB0907120D0 (en) * 2009-04-24 2009-06-03 Chroma Therapeutics Ltd Inhibitors of IKK-ß serine-threonine protein kinase
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
CA2888928C (en) 2012-10-17 2020-05-26 Macrophage Pharma Limited Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
ES2372707T3 (es) 2012-01-25
WO2008053182A1 (en) 2008-05-08
KR20090077975A (ko) 2009-07-16
JP2010508336A (ja) 2010-03-18
EP2078007A1 (en) 2009-07-15
EA200900616A1 (ru) 2010-04-30
BRPI0718056A2 (pt) 2013-11-05
ATE522516T1 (de) 2011-09-15
NZ576705A (en) 2011-12-22
EP2078007B1 (en) 2011-08-31
US20100087515A1 (en) 2010-04-08
MX2009004442A (es) 2009-05-22
US8003695B2 (en) 2011-08-23
IL198267A0 (en) 2009-12-24
DK2078007T3 (da) 2011-12-12
CA2668338A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
EP2078007B1 (en) Ikk-beta serine-threonine protein kinase inhibitors
EP2086956B1 (en) Inhibitors of ikk- beta serine-threonine protein kinase
US20110190306A1 (en) Inhibitors of PLK
AU2007246869B2 (en) p38 MAP kinase inhibitors
EP2079742A1 (en) Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
JP5732408B2 (ja) 酵素阻害剤
EP2297128B1 (en) Inhibitors of ikk- serine-threonine protein kinase
US20110046210A1 (en) Substituted thiopenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors
WO2008053158A1 (en) Inhibitors of p38 mitogen-activated protein kinase
CN101541779A (zh) IKK-β丝氨酸-苏氨酸蛋白激酶抑制剂
WO2008053136A1 (en) 2-(hetero-)aryl,4-carbonyl substituted pyrazole derivatives as inhibitors of p38 mitogen-activated protein kinase
EP2421844A1 (en) Thiophene inhibitors of ikk-b serine-threonine protein kinase
WO2009141575A1 (en) Inhibitors of plk
AU2006350475A1 (en) Hydroxamates as inhibitors of histone deacetylase

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application